Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab

17 Sept 2013

Abstract excerpt

Monoclonal antibody preparations have demonstrated considerable clinical utility in the treatment of specific malignancies, as well as inflammatory and infectious diseases. Antibodies are conventionally delivered by passive administration, typically requiring costly large-scale laboratory development and production. Additional limitations include the necessity for repeat administrations, and the length of in vivo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV Research and Treatment
Share to Monoclonal and Polyclonal Antibodies Research
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24045230
DOI: 10.4161/hv.26498

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein FabPMID 24045230Read ↗

Antibody gene transfer with adeno‐associated viral vectors as a method for HIV preventionSemantic proximity Read ↗

Adeno-Associated Viral Vector Mediated Expression of Broadly- Neutralizing Antibodies Against HIV-Hitting a Fast-Moving Target.Semantic proximity Read ↗

Antibody-Directed Targeting of Retroviral Vectors via Cell Surface AntigensSemantic proximity Read ↗

DNA vaccines: prime time is nowSemantic proximity Read ↗

State of play and clinical prospects of antibody gene transferSemantic proximity Read ↗

Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate ModelSemantic proximity Read ↗

Antibody Engineering at the MillenniumSemantic proximity Read ↗

HIV DNA Vaccine: Stepwise Improvements Make a DifferenceSemantic proximity Read ↗

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse ModelSemantic proximity Read ↗

DNA immunization as a technology platform for monoclonal antibody inductionSemantic proximity Read ↗

Phase 1, dose-escalation trial of the safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies (DMAb) in healthy adultsSemantic proximity Read ↗

An Antibody Delivery System for Regulated Expression of Therapeutic Levels of Monoclonal Antibodies In VivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.